Extrawell Pharmaceutical Holdings Ltd banner
E

Extrawell Pharmaceutical Holdings Ltd
HKEX:858

Watchlist Manager
Extrawell Pharmaceutical Holdings Ltd
HKEX:858
Watchlist
Price: 0.083 HKD Market Closed
Market Cap: HK$211.7m

Multiples-Based Value

The Multiples-Based Value for Extrawell Pharmaceutical Holdings Ltd (858) under the Base Case is 0.034 HKD. Compared with the current market price of 0.083 HKD, the stock appears Overvalued by 59%.

Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

Multiples-Based Value
Base Case
0.034 HKD
Overvaluation 59%
Multiples-Based Value
Price HK$0.083
E
Worst Case
Base Case
Best Case

Multiples Across Competitors

Competitors Multiples
Extrawell Pharmaceutical Holdings Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
HK
Extrawell Pharmaceutical Holdings Ltd
HKEX:858
211.7m HKD 4 -0.6 -22.4 -22.4
US
Eli Lilly and Co
NYSE:LLY
900.7B USD 13.8 43.6 29.4 31.4
US
Johnson & Johnson
NYSE:JNJ
581B USD 6.2 21.7 15.1 18.5
UK
AstraZeneca PLC
LSE:AZN
236B GBP 5.3 30.3 16.8 23.6
CH
Roche Holding AG
SIX:ROG
248.4B CHF 4.1 19.4 11.5 13
US
Merck & Co Inc
NYSE:MRK
304.8B USD 4.7 16.7 10.3 12.6
CH
Novartis AG
SIX:NOVN
232.5B CHF 5.1 20.7 12.8 16.5
IE
Endo International PLC
LSE:0Y5F
244.4B USD 105.4 -83.6 386.8 970
DK
Novo Nordisk A/S
CSE:NOVO B
1.1T DKK 3.4 10.3 7.6 9
US
Pfizer Inc
NYSE:PFE
156.2B USD 2.5 20.1 7.7 10.3
US
Bristol-Myers Squibb Co
NYSE:BMY
119.2B USD 2.5 16.9 7.1 8.8
P/E Multiple
Earnings Growth PEG
HK
E
Extrawell Pharmaceutical Holdings Ltd
HKEX:858
Average P/E: 22.2
Negative Multiple: -0.6
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
43.6
32%
1.4
US
Johnson & Johnson
NYSE:JNJ
21.7
7%
3.1
UK
AstraZeneca PLC
LSE:AZN
30.3
26%
1.2
CH
Roche Holding AG
SIX:ROG
19.4
14%
1.4
US
Merck & Co Inc
NYSE:MRK
16.7
14%
1.2
CH
Novartis AG
SIX:NOVN
20.7
14%
1.5
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -83.6 N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
10.3
1%
10.3
US
Pfizer Inc
NYSE:PFE
20.1
22%
0.9
US
Bristol-Myers Squibb Co
NYSE:BMY
16.9
16%
1.1
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
HK
E
Extrawell Pharmaceutical Holdings Ltd
HKEX:858
Average EV/EBITDA: 50.5
Negative Multiple: -22.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
29.4
22%
1.3
US
Johnson & Johnson
NYSE:JNJ
15.1
2%
7.5
UK
AstraZeneca PLC
LSE:AZN
16.8
13%
1.3
CH
Roche Holding AG
SIX:ROG
11.5
6%
1.9
US
Merck & Co Inc
NYSE:MRK
10.3
3%
3.4
CH
Novartis AG
SIX:NOVN
12.8
5%
2.6
IE
E
Endo International PLC
LSE:0Y5F
386.8
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
7.6
1%
7.6
US
Pfizer Inc
NYSE:PFE
7.7
-9%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
7.1
-10%
N/A
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
HK
E
Extrawell Pharmaceutical Holdings Ltd
HKEX:858
Average EV/EBIT: 111.4
Negative Multiple: -22.4
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
31.4
22%
1.4
US
Johnson & Johnson
NYSE:JNJ
18.5
6%
3.1
UK
AstraZeneca PLC
LSE:AZN
23.6
21%
1.1
CH
Roche Holding AG
SIX:ROG
13
6%
2.2
US
Merck & Co Inc
NYSE:MRK
12.6
6%
2.1
CH
Novartis AG
SIX:NOVN
16.5
9%
1.8
IE
E
Endo International PLC
LSE:0Y5F
970
N/A N/A
DK
Novo Nordisk A/S
CSE:NOVO B
9
2%
4.5
US
Pfizer Inc
NYSE:PFE
10.3
-4%
N/A
US
Bristol-Myers Squibb Co
NYSE:BMY
8.8
-7%
N/A
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett